Uterine Cervical NeoplasmsNCT07702838
Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
A study testing Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy. in people with Uterine Cervical Neoplasms, run by Zhejiang Cancer Hospital at 1 site in China.
Trial summary
This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Uterine Cervical Neoplasms
- What is being tested?
- Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- Jul 2026to Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Female patients aged ≥ 18 years at the time of signing the informed consent form.
- Histopathologically confirmed diagnosis of cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma).
- Stage IIB-IVA disease per the 2018 FIGO staging system.
- Presence of measurable lesions as defined by RECIST version 1.1.
- Patients reviewed by the carbon ion radiotherapy multidisciplinary team (MDT) with an indication for carbon ion radiotherapy.
- Patients voluntarily receiving carbon ion radiotherapy at Zhejiang Cancer Hospital and bearing all relevant treatment expenses.
Show all 14Show fewer
- Complete clinical and imaging data available.
- Patients willing to participate in the trial and complete questionnaire surveys.
- Patients willing to participate in the trial and provide biospecimens, including cervical tissue, various body fluid specimens and tissue samples.
- Patients willing to attend regular standardised outpatient follow-up visits at our hospital.
- Eastern Cooperative 11. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2.
- No prior history of surgery, radiotherapy or chemotherapy for cervical cancer.
- Adequate function of major vital organs (bone marrow, liver, kidney, etc.), with laboratory values meeting the following criteria within 1 week prior to treatment: Absolute neutrophil count (ANC) ≥ 1500/μL; Platelet count ≥ 100,000/μL; Haemoglobin ≥ 9.0 g/dL (or ≥ 5.6 mmol/L); Creatinine clearance ≥ 50 mL/min; Total bilirubin ≤ 1.5 × upper limit of normal (ULN); if total bilirubin > 1.5 × ULN, direct bilirubin shall be ≤ ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; International Normalised Ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (excluding patients receiving anticoagulant therapy within the therapeutic range).
- Estimated overall survival ≥ 6 months.
Who cannot join
- Presence of severe concomitant complications (e.g., uncontrolled cardiovascular disease, hypertension, diabetes mellitus, refractory infection, active peptic ulcer, uncontrolled psychiatric disorders, etc.)
- Concurrent active second primary malignancy.
- Tumour invasion of the rectum (Stage IVA) or peritoneal metastasis (M1).
- Prior receipt of immunotherapy agents (including anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.).
- Prior radical surgery, radiotherapy, or systemic therapy (including investigational agents) for cervical cancer. Note: Conisation of the cervix is permitted.
- Administration of any investigational drug within 4 weeks before the initiation of immunotherapy.
Show all 18Show fewer
- Confirmed immunodeficiency or receipt of chronic systemic corticosteroid therapy (prednisone equivalent dose >10 mg/day) or other immunosuppressive therapy within 7 days prior to immunotherapy.
- History of grade ≥3 severe hypersensitivity reactions to immunotherapeutic agents.
- Active autoimmune disease requiring systemic therapy within the past 2 years (replacement therapies such as thyroxine, insulin and physiological glucocorticoids are excluded).
- Prior history of non-infectious pneumonitis/interstitial lung disease requiring steroid treatment, or current active pneumonitis/interstitial lung disease.
- Active infection requiring systemic treatment.
- History of active hepatitis B (HBsAg positive) or active hepatitis C (detectable HCV RNA).
- Any disease, treatment, laboratory abnormality or other condition that, in the investigator's judgement, may confound study results, hinder full study participation or pose additional risks to the subject.
- Known psychiatric illness or substance abuse that may impair subject compliance; pregnant or breastfeeding females, or those planning conception/pregnancy during the study period (from screening to 120 days after the last study treatment).
- Previous allogeneic tissue or solid organ transplantation.
- History of HIV infection.
- Metallic implants within the radiation field path that may compromise the accuracy of radiotherapy dose calculation.
- Subject requests withdrawal from the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Zhuomin Yin, MD contact
China1 site, 1 recruiting
- Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022
Zhuomin Yin, MD, yinzm@zjcc.org.cn
About this study
Official title: A Prospective Clinical Study of Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.
Read the detailed description
The primary objective of this study is to explore whether carbon ion radiotherapy combined with immunotherapy and chemotherapy can improve the 2-year progression-free survival (PFS) of patients with locally advanced cervical cancer (Stage IIB-IVA). The secondary objectives are to investigate whether this regimen can improve the 2-year overall survival (OS) of patients with locally advanced cervical cancer, and to evaluate the adverse events associated with carbon ion radiotherapy combined with immunotherapy and chemotherapy based on RTOG and CTCAE criteria.
- Conditions
- Uterine Cervical Neoplasms
- Being tested
- Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.
- Keywords
- Carbon Ion Radiotherapy, Immunotherapy, Chemotherapy, Survival Outcome, Uterine Cervical Neoplasms
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.Radiation
Also called Immunotherapy: Anti-PD-1 therapy, Chemotherapy
Immunotherapy: Anti-PD-1 therapy administered once every 3 weeks starting at radiotherapy initiation, with a total maintenance duration of 2 years. Chemotherapy: Weekly concurrent single-agent cisplatin (dose: 40 mg/m² per week) or carboplatin (target AUC = 2) is given simultaneously with carbon ion external beam radiotherapy for a total of 4 cycles.
| Study group | Role | What they receive |
|---|---|---|
| Immunotherapy Combined with Carbon Ion Radiotherapy and Concurrent Chemotherapy for Locally Advanced | Experimental | Immunotherapy: Anti-PD-1 therapy administered once every 3 weeks starting at radiotherapy initiation, with a total maintenance duration of 2 years.
Chemotherapy: Weekly concurrent single-agent cisplatin (dose: 40 mg/m² per week) or carboplatin (target AUC = 2) given simultaneously with carbon ion external beam radiotherapy, for a total of 4 cycles.
Radiotherapy: Carbon ion external beam radiotherapy plus 3 courses of three-dimensional intracavitary brachytherapy. Receives: Radiation: Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free survival (PFS)
This endpoint is determined based on investigators' assessments per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). If disease progression cannot be confirmed by imaging according to RECIST 1.1, progressive disease (PD) histopathologically verified following carbon ion radiotherapy combined with three-dimensional brachytherapy, concurrent chemotherapy and immunotherapy shall serve as the criterion for progression determination.
Measured: At 2 years after the start of trial treatment
Secondary outcomes (2)
Overall survival (OS)
To evaluate the 2-year overall survival rate of patients treated with carbon ion radiotherapy plus three-dimensional intracavitary brachytherapy combined with concurrent chemotherapy and immunotherapy. Death from any cause is defined as the endpoint event. Subjects who remain alive or are lost to follow-up at the data cut-off date will be treated as censored data.
Measured: At 2 years after the start of trial treatment
Acute and late toxicities
To evaluate acute and late toxicities of carbon ion radiotherapy plus three-dimensional intracavitary brachytherapy combined with concurrent chemotherapy and immunotherapy, graded per RTOG and CTCAE criteria.
Measured: Acute toxicities: AEs within 90 days of carbon ion radiotherapy start, graded per CTCAE & RTOG acute radiation morbidity criteria. Late toxicities: Radiation-associated tissue injuries new or worsening >90 days after the star radiotherapy initiation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study startJul 2026 (estimated)
- Primary completionDec 2029 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (24)Papers the sponsor has linked to this study.
- Other trials for Uterine Cervical NeoplasmsStudies of the same condition, open and under way.
- More trials run by Zhejiang Cancer HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective single-arm clinical study
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhejiang Cancer Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yin ZhuoMin, Zhejiang Cancer Hospital
- Investigators
- Hanmei Lou, MD, Study chair, Zhejiang Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07702838
- Sponsor's protocol ID
- IRB-2026-877（IIT）
- Status last verified
- Jul 2026
- First submitted
- 29 Jun 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared publicly due to limitations of institutional data repository, privacy protection of cervical cancer patients, and lack of dedicated funding for data curation and management.
Publications
Azzam AY, Ghozy S, Kallmes KM, Adusumilli G, Heit JJ, Hassan AE, Kadirvel R, Kallmes DF. Aspiration thrombectomy versus stent retriever thrombectomy alone for acute ischemic stroke: evaluating the overlapping meta-analyses. J Neurointerv Surg. 2023 Jan;15(1):34-38. doi: 10.1136/neurintsurg-2022-018849. Epub 2022 May 18.
PubMed 35584912Wakatsuki M, Kato S, Kiyohara H, Ohno T, Karasawa K, Tamaki T, Ando K, Tsujii H, Nakano T, Kamada T, Shozu M; Working Group of the Gynecological Tumor. Clinical trial of prophylactic extended-field carbon-ion radiotherapy for locally advanced uterine cervical cancer (protocol 0508). PLoS One. 2015 May 20;10(5):e0127587. doi: 10.1371/journal.pone.0127587. eCollection 2015.
PubMed 25993047Wakatsuki M, Kato S, Ohno T, Karasawa K, Ando K, Kiyohara H, Tsujii H, Nakano T, Kamada T, Shozu M; Working Group of the Gynecological Tumor. Dose-escalation study of carbon ion radiotherapy for locally advanced squamous cell carcinoma of the uterine cervix (9902). Gynecol Oncol. 2014 Jan;132(1):87-92. doi: 10.1016/j.ygyno.2013.10.021. Epub 2013 Oct 29.
PubMed 24183732Jahangir Z, Bakillah A, Iqbal J. Regulation of Sphingolipid Metabolism by MicroRNAs: A Potential Approach to Alleviate Atherosclerosis. Diseases. 2018 Sep 17;6(3):82. doi: 10.3390/diseases6030082.
PubMed 30227643Elmanfi S, Ma X, Sintim HO, Kononen E, Syrjanen S, Gursoy UK. Quorum-sensing molecule dihydroxy-2,3-pentanedione and its analogs as regulators of epithelial integrity. J Periodontal Res. 2018 Jun;53(3):414-421. doi: 10.1111/jre.12528. Epub 2018 Jan 17.
PubMed 29344966Laserson U, Vigneault F, Gadala-Maria D, Yaari G, Uduman M, Vander Heiden JA, Kelton W, Taek Jung S, Liu Y, Laserson J, Chari R, Lee JH, Bachelet I, Hickey B, Lieberman-Aiden E, Hanczaruk B, Simen BB, Egholm M, Koller D, Georgiou G, Kleinstein SH, Church GM. High-resolution antibody dynamics of vaccine-induced immune responses. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4928-33. doi: 10.1073/pnas.1323862111. Epub 2014 Mar 17.
PubMed 24639495Zhang G, Zhang Z, Pei Y, Hu W, Xue Y, Ning R, Guo X, Sun Y, Zhang Q. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics. Front Endocrinol (Lausanne). 2023 Oct 20;14:1272806. doi: 10.3389/fendo.2023.1272806. eCollection 2023.
PubMed 38027108Buizza G, Paganelli C, D'Ippolito E, Fontana G, Molinelli S, Preda L, Riva G, Iannalfi A, Valvo F, Orlandi E, Baroni G. Radiomics and Dosiomics for Predicting Local Control after Carbon-Ion Radiotherapy in Skull-Base Chordoma. Cancers (Basel). 2021 Jan 18;13(2):339. doi: 10.3390/cancers13020339.
PubMed 33477723Ma L, Li Y, Sakamoto Y, Xie L, Suzuki S, Yoshida Y, Sui L, Guo G, Wen J, Ren W, Kakimi K, Osada K, Takahashi A, Shimokawa T. Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody. Neoplasia. 2025 Feb;60:101099. doi: 10.1016/j.neo.2024.101099. Epub 2024 Dec 13.
PubMed 39674115Shiba S, Okonogi N, Kato S, Wakatsuki M, Kobayashi D, Kiyohara H, Ohno T, Karasawa K, Nakano T, Kamada T. Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers. Anticancer Res. 2017 Oct;37(10):5577-5583. doi: 10.21873/anticanres.11991.
PubMed 28982873Okonogi N, Ando K, Murata K, Wakatsuki M, Noda SE, Irie D, Tsuji H, Shozu M, Ohno T. Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix. Cancers (Basel). 2021 May 31;13(11):2713. doi: 10.3390/cancers13112713.
PubMed 34072676Wang X, Chen X, Li G, Han X, Gao T, Liu W, Tang X. Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review. Front Oncol. 2021 Jul 5;11:708724. doi: 10.3389/fonc.2021.708724. eCollection 2021.
PubMed 34290989Tinganelli W, Durante M. Carbon Ion Radiobiology. Cancers (Basel). 2020 Oct 17;12(10):3022. doi: 10.3390/cancers12103022.
PubMed 33080914Reinhardt JM, Christensen GE, Hoffman EA, Ding K, Cao K. Registration-derived estimates of local lung expansion as surrogates for regional ventilation. Inf Process Med Imaging. 2007;20:763-74. doi: 10.1007/978-3-540-73273-0_63.
PubMed 17633746Paskett ED. Breast cancer-related lymphedema: attention to a significant problem resulting from cancer diagnosis. J Clin Oncol. 2008 Dec 10;26(35):5666-7. doi: 10.1200/JCO.2008.19.0850. Epub 2008 Nov 10. No abstract available.
PubMed 19001317
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Clinical Study of Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
- ClinicalTrials.gov ID
- NCT07702838
- Acronym / sponsor ID
- IRB-2026-877（IIT）
- Conditions
- Uterine Cervical Neoplasms
- Keywords
- Carbon Ion Radiotherapy, Immunotherapy, Chemotherapy, Survival Outcome, Uterine Cervical Neoplasms
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Zhejiang Cancer HospitalUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Dec 2029 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.
Detailed description
The primary objective of this study is to explore whether carbon ion radiotherapy combined with immunotherapy and chemotherapy can improve the 2-year progression-free survival (PFS) of patients with locally advanced cervical cancer (Stage IIB-IVA). The secondary objectives are to investigate whether this regimen can improve the 2-year overall survival (OS) of patients with locally advanced cervical cancer, and to evaluate the adverse events associated with carbon ion radiotherapy combined with immunotherapy and chemotherapy based on RTOG and CTCAE criteria.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective single-arm clinical study
| Arm | Type | Receives |
|---|---|---|
| Immunotherapy Combined with Carbon Ion Radiotherapy and Concurrent Chemotherapy for Locally Advanced | Experimental | Radiation: Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.Immunotherapy: Anti-PD-1 therapy administered once every 3 weeks starting at radiotherapy initiation, with a total maintenance duration of 2 years. Chemotherapy: Weekly concurrent single-agent cisplatin (dose: 40 mg/m² per week) or carboplatin (target AUC = 2) given simultaneously with carbon ion external beam radiotherapy, for a total of 4 cycles. Radiotherapy: Carbon ion external beam radiotherapy plus 3 courses of three-dimensional intracavitary brachytherapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Female patients aged ≥ 18 years at the time of signing the informed consent form.
- Histopathologically confirmed diagnosis of cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma).
- Stage IIB-IVA disease per the 2018 FIGO staging system.
- Presence of measurable lesions as defined by RECIST version 1.1.
- Patients reviewed by the carbon ion radiotherapy multidisciplinary team (MDT) with an indication for carbon ion radiotherapy.
Key exclusion criteria (18 listed)
- Presence of severe concomitant complications (e.g., uncontrolled cardiovascular disease, hypertension, diabetes mellitus, refractory infection, active peptic ulcer, uncontrolled psychiatric disorders, etc.)
- Concurrent active second primary malignancy.
- Tumour invasion of the rectum (Stage IVA) or peritoneal metastasis (M1).
- Prior receipt of immunotherapy agents (including anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.).
- Prior radical surgery, radiotherapy, or systemic therapy (including investigational agents) for cervical cancer. Note: Conisation of the cervix is permitted.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy.Also: Immunotherapy: Anti-PD-1 therapy, ChemotherapyImmunotherapy: Anti-PD-1 therapy administered once every 3 weeks starting at radiotherapy initiation, with a total maintenance duration of 2 years. Chemotherapy: Weekly concurrent single-agent cisplatin (dose: 40 mg/m² per week) or carboplatin (target AUC = 2) is given simultaneously with carbon ion external beam radiotherapy for a total of 4 cycles. | Radiation | Immunotherapy Combined with Carbon Ion Radiotherapy and Concurrent Chemotherapy for Locally Advanced |
Primary outcome
Progression-free survival (PFS)
Time frame: At 2 years after the start of trial treatment
This endpoint is determined based on investigators' assessments per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). If disease progression cannot be confirmed by imaging according to RECIST 1.1, progressive disease (PD) histopathologically verified following carbon ion radiotherapy combined with three-dimensional brachytherapy, concurrent chemotherapy and immunotherapy shall serve as the criterion for progression determination.
2 secondary outcomes
Overall survival (OS)
Time frame: At 2 years after the start of trial treatment
Acute and late toxicities
Time frame: Acute toxicities: AEs within 90 days of carbon ion radiotherapy start, graded per CTCAE & RTOG acute radiation morbidity criteria. Late toxicities: Radiation-associated tissue injuries new or worsening >90 days after the star radiotherapy initiation.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Background: PubMed 35584912Azzam AY, Ghozy S, Kallmes KM, Adusumilli G, Heit JJ, Hassan AE, Kadirvel R, Kallmes DF. Aspiration thrombectomy versus stent retriever thrombectomy alone for acute ischemic stroke: evaluating the overlapping meta-analyses. J Neurointerv Surg. 2023 Jan;15(1):34-38. doi: 10.1136/neurintsurg-2022-018849. Epub 2022 May 18.
- Background: PubMed 25993047Wakatsuki M, Kato S, Kiyohara H, Ohno T, Karasawa K, Tamaki T, Ando K, Tsujii H, Nakano T, Kamada T, Shozu M; Working Group of the Gynecological Tumor. Clinical trial of prophylactic extended-field carbon-ion radiotherapy for locally advanced uterine cervical cancer (protocol 0508). PLoS One. 2015 May 20;10(5):e0127587. doi: 10.1371/journal.pone.0127587. eCollection 2015.
- Background: PubMed 24183732Wakatsuki M, Kato S, Ohno T, Karasawa K, Ando K, Kiyohara H, Tsujii H, Nakano T, Kamada T, Shozu M; Working Group of the Gynecological Tumor. Dose-escalation study of carbon ion radiotherapy for locally advanced squamous cell carcinoma of the uterine cervix (9902). Gynecol Oncol. 2014 Jan;132(1):87-92. doi: 10.1016/j.ygyno.2013.10.021. Epub 2013 Oct 29.
- Background: PubMed 30227643Jahangir Z, Bakillah A, Iqbal J. Regulation of Sphingolipid Metabolism by MicroRNAs: A Potential Approach to Alleviate Atherosclerosis. Diseases. 2018 Sep 17;6(3):82. doi: 10.3390/diseases6030082.
- Background: PubMed 29344966Elmanfi S, Ma X, Sintim HO, Kononen E, Syrjanen S, Gursoy UK. Quorum-sensing molecule dihydroxy-2,3-pentanedione and its analogs as regulators of epithelial integrity. J Periodontal Res. 2018 Jun;53(3):414-421. doi: 10.1111/jre.12528. Epub 2018 Jan 17.
- Background: PubMed 24639495Laserson U, Vigneault F, Gadala-Maria D, Yaari G, Uduman M, Vander Heiden JA, Kelton W, Taek Jung S, Liu Y, Laserson J, Chari R, Lee JH, Bachelet I, Hickey B, Lieberman-Aiden E, Hanczaruk B, Simen BB, Egholm M, Koller D, Georgiou G, Kleinstein SH, Church GM. High-resolution antibody dynamics of vaccine-induced immune responses. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4928-33. doi: 10.1073/pnas.1323862111. Epub 2014 Mar 17.
- Background: PubMed 38027108Zhang G, Zhang Z, Pei Y, Hu W, Xue Y, Ning R, Guo X, Sun Y, Zhang Q. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics. Front Endocrinol (Lausanne). 2023 Oct 20;14:1272806. doi: 10.3389/fendo.2023.1272806. eCollection 2023.
- Background: PubMed 33477723Buizza G, Paganelli C, D'Ippolito E, Fontana G, Molinelli S, Preda L, Riva G, Iannalfi A, Valvo F, Orlandi E, Baroni G. Radiomics and Dosiomics for Predicting Local Control after Carbon-Ion Radiotherapy in Skull-Base Chordoma. Cancers (Basel). 2021 Jan 18;13(2):339. doi: 10.3390/cancers13020339.
- Background: PubMed 39674115Ma L, Li Y, Sakamoto Y, Xie L, Suzuki S, Yoshida Y, Sui L, Guo G, Wen J, Ren W, Kakimi K, Osada K, Takahashi A, Shimokawa T. Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody. Neoplasia. 2025 Feb;60:101099. doi: 10.1016/j.neo.2024.101099. Epub 2024 Dec 13.
- Background: PubMed 28982873Shiba S, Okonogi N, Kato S, Wakatsuki M, Kobayashi D, Kiyohara H, Ohno T, Karasawa K, Nakano T, Kamada T. Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers. Anticancer Res. 2017 Oct;37(10):5577-5583. doi: 10.21873/anticanres.11991.
- Background: PubMed 34072676Okonogi N, Ando K, Murata K, Wakatsuki M, Noda SE, Irie D, Tsuji H, Shozu M, Ohno T. Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix. Cancers (Basel). 2021 May 31;13(11):2713. doi: 10.3390/cancers13112713.
- Background: PubMed 34290989Wang X, Chen X, Li G, Han X, Gao T, Liu W, Tang X. Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review. Front Oncol. 2021 Jul 5;11:708724. doi: 10.3389/fonc.2021.708724. eCollection 2021.
- Individual participant dataSharing planned: No. Individual participant data will not be shared publicly due to limitations of institutional data repository, privacy protection of cervical cancer patients, and lack of dedicated funding for data curation and management.
Related trials for Uterine Cervical Neoplasms
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 4
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Cervical Cancer
Recruiting
Use Misoprostol to Optimize Prevention of Cervical Cancer
Cervical Cancers
RecruitingObservational study
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
Cervical Cancer, Cervical Dysplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Zhuomin Yin, MD contact
Hanmei Lou, MD study chair
Zhejiang Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Carbon ion external beam radiotherapy plus 3 courses of three-dimensional brachytherapy. in people with Uterine Cervical Neoplasms, run by Zhejiang Cancer Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zhuomin Yin, MD (yinzm@zjcc.org.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free survival (PFS) (time frame: At 2 years after the start of trial treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07702838, which also lists 24 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.